Chemotherapy for Mantle Cell Lymphoma Pleomorphic Variant

Treatment Approach

The European Society for Medical Oncology recommends that treatment for the pleomorphic variant of mantle cell lymphoma should follow the same intensive approaches used for blastoid MCL, with younger fit patients receiving cytarabine-containing regimens followed by autologous stem cell transplantation, while older or less fit patients should receive bendamustine-rituximab (BR) or VR-CAP rather than R-CHOP alone 1, 2
The optimal induction regimen consists of rituximab-containing chemotherapy with high-dose cytarabine followed by autologous stem cell transplantation (ASCT), as recommended by the European Society for Medical Oncology 1, 2, 3

A randomized trial demonstrated that cytarabine-containing induction achieves significantly improved median time to treatment failure (P = 0.038) compared to regimens without cytarabine, with a strength of evidence rated as high 1, 2, 3
The recommended approach is R-CHOP alternating with high-dose cytarabine (HD-Ara-C) followed by ASCT consolidation, with a median progression-free survival of 35 months 4, 1, 2
BR demonstrated superior progression-free survival compared to R-CHOP (median PFS 35 vs 21 months) with better tolerability, and is recommended by the National Comprehensive Cancer Network 1, 2

Rituximab maintenance significantly improves both progression-free survival and overall survival and should be administered after induction therapy, as recommended by the European Society for Medical Oncology 1, 2, 3
After R-CHOP, rituximab maintenance provides PFS and OS benefit in patients ≥60 years, with a hazard ratio of 0.73 1, 2, 3
Rituximab maintenance is administered until disease progression, with a recommended dose of 375 mg/m² every 8 weeks 7

The pleomorphic variant represents approximately 5% of MCL cases and behaves similarly to blastoid MCL with aggressive clinical features requiring intensive therapy approaches, according to the World Health Organization 7
Pleomorphic MCL is classified alongside blastoid MCL as "transformed" MCL with high proliferation rates and complex karyotypes, and requires the same intensive treatment strategies as blastoid MCL rather than approaches used for classical MCL 7
Avoid watch-and-wait strategies that might be considered for indolent classical MCL, as they are not recommended for pleomorphic MCL 7